Nicole Pfarr, Dipl.-Biol, discusses how tumor whole exome sequencing (WES) can provide valuable insights into mechanisms that drive tumor proliferation, survival, and response to therapy. WES has the potential of finding new biomarkers for targeted-therapy such as antibody-drug conjugates (ADCs). Nicole Pfarr, Dipl.-Biol, is the head of the Molecular Pathology Diagnostic Unit and of the Next Generation Sequencing Research Facility at the Technical University of Munich, Germany. Learn about WGS: https://youtu.be/19sH2UQMLAA?si=u8M2F8ti_zVDQ70x Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM LinkedIn: https://www.linkedin.com/company/illumina X: https://x.com/illumina Instagram: https://www.instagram.com/illuminainc/ Facebook: https://www.facebook.com/illuminainc TikTok: https://www.tiktok.com/@illuminainc #WES #multiomics #Illumina